dc.contributor | Centro de Reprodução Humana Prof. Franco Junior | |
dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.contributor | Universidade de Santo Amaro | |
dc.contributor | Centro de Reprodução Humana Prof. Franco Junior, Ribeirão Preto | |
dc.date.accessioned | 2014-05-27T11:22:00Z | |
dc.date.accessioned | 2022-10-05T18:03:26Z | |
dc.date.available | 2014-05-27T11:22:00Z | |
dc.date.available | 2022-10-05T18:03:26Z | |
dc.date.created | 2014-05-27T11:22:00Z | |
dc.date.issued | 2006-10-01 | |
dc.identifier | Jornal Brasileiro de Reproducao Assistida, v. 10, n. 4, p. 9-16, 2006. | |
dc.identifier | 1517-5693 | |
dc.identifier | 1518-0557 | |
dc.identifier | http://hdl.handle.net/11449/69156 | |
dc.identifier | 2-s2.0-33847306557 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3918632 | |
dc.description.abstract | The purpose of this investigation was to verify the efficacy of recombinant LH supplementation for controlled ovarian stimulation in GnRH-antagonist protocol for assisted reproductive technologies cycles. Search strategies included on-line surveys of databases from 1990 to 2006. In this review and meta-analysis, the observed advantages for the LH supplementation protocol were a higher serum estradiol levels on the day of hCG administration and a higher number of mature oocytes. However, there were no differences observed in the total amount of r-FSH administered, days of stimulation, number of oocyte retrieved, the clinical pregnancy rate per oocyte retrieval, the implantation rate and miscarriage rate. This result demonstrates that the association of r-LH with r-FSH may prevent any decrease in estradiol after antagonist administration and a significant higher number of mature oocytes was obtained. Nevertheless, additional randomized controlled trials are needed confirm these observations. | |
dc.language | por | |
dc.relation | Jornal Brasileiro de Reproducao Assistida | |
dc.relation | 0,282 | |
dc.rights | Acesso aberto | |
dc.source | Scopus | |
dc.subject | GnRH antagonist | |
dc.subject | Ovarian stimulation | |
dc.subject | Recombinant FSH | |
dc.subject | Recombinant LH | |
dc.subject | cetrorelix | |
dc.subject | chorionic gonadotropin | |
dc.subject | estradiol | |
dc.subject | ethinylestradiol | |
dc.subject | ethinylestradiol plus gestodene | |
dc.subject | gonadorelin antagonist | |
dc.subject | levonorgestrel | |
dc.subject | oral contraceptive agent | |
dc.subject | recombinant follitropin | |
dc.subject | recombinant luteinizing hormone | |
dc.subject | clinical trial | |
dc.subject | combination chemotherapy | |
dc.subject | data base | |
dc.subject | drug dose regimen | |
dc.subject | drug efficacy | |
dc.subject | drug mechanism | |
dc.subject | estradiol blood level | |
dc.subject | hormone substitution | |
dc.subject | human | |
dc.subject | low drug dose | |
dc.subject | meta analysis | |
dc.subject | monotherapy | |
dc.subject | oocyte | |
dc.subject | ovary function | |
dc.subject | pregnancy rate | |
dc.subject | spontaneous abortion | |
dc.subject | systematic review | |
dc.title | O emprego de hormônio luteinizante recombinante associado ao hormônio folículo-estimulante recombinante nos protocolos de estimulação ovariana com antagonista do GnRH | |
dc.type | Artigo | |